Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation
Y-F Chen, S Jowett, P Barton, K Malottki, C Hyde, JSR Gibbs, J Pepke-Zaba, A Fry-Smith, J Roberts, D Moore
Health Technology Assessment | NIHR JOURNALS LIBRARY | Published : 2009
Awarded by Medical Research Council
The licence for the GPRD was funded by the European Commission via the Taskforce European Drug Development for the Young (TEDDY) network of Excellence European Commission Framework 6 Programme 2005-2010.